Educational Activities-- Satellite Symposia
Information as of: October 8, 2008
Joint Meeting Satellite Symposia
October 24 – 28, 2008
Satellite symposia are non-commercial scientific sessions supported by Joint Meeting exhibitors to complement the official program and to extend the educational experience of meeting attendees. They may include one or a number of speakers and may cover one or several topics, but they must offer objectivity in the presentation. Satellite symposia are not part of the official Joint Meeting scientific sessions as planned by the Joint Program Committee.
Satellite Symposia will be held over five days, outside the schedule of official Joint Meeting activities.
All Satellite Symposia will be held at the Grand Hyatt Washington (a headquarters hotel located 3 blocks from the center), the Renaissance Washington (a headquarters hotel across from the center), and the Washington Convention Center.
SCHEDULE
Friday, October 24
Clostridium difficile Infections: Current Challenges & Treatments
Sponsored by Optimer Pharmaceuticals, Inc.
Registration and Dinner: 5:30 - 6:00 PM
Presentations: 6:00 - 8:00 PM
Location: Washington Convention Center, Ballroom C
The symposium will review the changing epidemiology of C. difficile infections. Surveillance and infection control measures and the potential benefits and limitations of currently available and investigational therapeutics will also be discussed.
MRSA: Evolving Bacteria Need Changing Paradigms
Sponsored by Arpida
Registration and Dinner: 6:00 - 6:30 PM
Presentations: 6:30 - 8:00 PM
Location: Washington Convention Center, Ballroom A Register online at:
www.ExemplarCE.org/RegArp/registration.asp
Infectious disease physicians have come to realize that serious, life-threatening infections, particularly MRSA, continue to result in unacceptably high levels of morbidity and mortality. To help stem the high morbidity and mortality rates associated with MRSA, infectious disease specialists require education on the types of infections, potential pathogens involved, current treatment guidelines, and the role of newer antimicrobial agents in the management of MRSA. This live symposium will highlight methicillin-resistant Staphylococcus aureus (MRSA), and will compare and contrast conventional and emerging antimicrobial therapies. Key teaching areas include current and future MRSA guidelines and how past, present, and future therapies fit into these guidelines.
Saturday, October 25
Immunization to Prevent Meningococcal Disease: Yesterday, Today, and Tomorrow
Sponsored by Novartis Vaccines
Registration and Breakfast: 6:00 - 6:30 AM
Presentations: 6:30 - 9:00 AM
Location: Grand Hyatt Washington, Constitution AB Register online at:
http://preventmd.cme360.net/default.aspx
This symposium will address the key learning areas of epidemiology, vaccine strategies, optimization of current approaches and anticipation of future opportunities for interventions by focusing on the past, present, and future of meningococcal imunization. Consideration of the identified learning gaps and diversity of audience attending a large international conference suggests a broad-based temporal perspective on prevention of invasive meningococcal disease through immunization is needed. This strategy allows for compelling and cohesive content and will integrate the relevant topics into an activity of interest to providers from different specialties.
MRSA and Mycoses: Tough Problems, New Solutions
Sponsored by Basilea Pharmaceuticals
Breakfast: 6:15 - 6:45 AM
Symposium: 6:45 - 9:00 AM
Location: Grand Hyatt Washington, Independence A Register online at:
http://Infection.haymarketmedical.com
As the rate of infections continues to occur at challenging levels because of the growing size of at-risk populations, physicians who regularly care for hospitalized patients require a constant state of vigilance in the recognition of at-risk patients as well as awareness of effective methods of infection management. This symposium will focus on management strategies for patients with MRSA, invasive aspergillosis, and deeply invasive candidiasis, as well as the current status of the newer azoles: voriconazole, posaconazole, and isavuconazole.
Saturday, October 25 (cont.)
Clostridium difficile Infection: Challenges and Controversies
Sponsored by ViroPharma, Incorporated
Registration and Dinner: 7:30 - 8:00 PM
Presentations: 8:00 - 10:30 PM
Location: Washington Convention Center, Ballroom A Register online at:
http://www.RMEI.com/CDI052
Join Us for an Interactive Panel Discussion! The epidemiology of Clostridium difficile infection is changing and has been marked by increasing rates and more severe and complicated disease. Furthermore, a virulent epidemic strain continues to be reported in an expanding list of states across the United States, and worldwide. Healthcare professionals should be aware of the importance of early recognition and prompt initiation of therapy; the preferred strategy for diagnosis; recognition of markers of severe disease; appropriate therapies based on disease severity; management of severe and recurrent disease; and effective prevention and control measures.
The Role of Integrase Inhibitors in HIV Management
Sponsored by Merck
Reception: 7:30 - 8:00 PM
Presentations: 8:00 - 10:00 PM
Location: Washington Convention Center, Room 146
Register online at:
http://clinicaloptions.com/IntegraseRole
A CME-certified satellite symposium designed to communicate the latest data on the mechanism of action, safety, and efficacy of integrase inhibitors, and the role of these agents in practical patient management strategies, through a combination of didactic and case-based content.
Capitalizing on What We Know About Gram-Positive Organisms: Three Bad Bugs - The Battle Continues
Sponsored by Targanta Therapeutics
Registration and Dinner: 7:30 - 8:15 PM
Presentations: 8:15 - 10:30 PM
Location: Washington Convention Center, Ballroom C
Register online at:
www.BadBugsSymposium.com
The emergence of gram-positive infections (MRSA, C. difficile, VRE, e.g.) has presen ted an enormous management challenge to researchers, clinicians, and patients. Recent investigational advances offer some promise on addressing these challenges. This symposium will present case studies of successful management techniques from numerous perspectives, including the surgeon, the emergency room physician, and the infectious disease specialist. These multi-disciplinary insights will shed important light onto this complex subject. The symposium will also provide an overview of the burden of illness due to gram-positive infections as well as share the latest drug discovery research in this area, thus allowing attendees valuable insight into potential future treatment strategies.
Sunday, October 26
CMV Disease in Transplant Recipients: Clinical Cases and Expert Opinion
Sponsored by ViroPharma, Incorporated
Registration and Dinner: 7:30 - 8:00 PM
Presentations: 8:00 - 10:30 PM
Location: Washington Convention Center, Ballroom C
Register online at:
www.RMEI.com/CMV053
Join Us for an Interactive Panel Discussion!
Cytomegalovirus (CMV) infection is an important cause of morbidity and mortality in recipients of hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT). Despite significant progress in elucidating the pathophysiology of CMV infection and the spectrum of disease in transplant recipients, diagnostic and therapeutic challenges remain. This symposium will discuss challenges, strategies, and treatment options for healthcare professionals who treat HSCT and SOT recipients.
Current Challenges in the Treatment of Patients Hospitalized for Community-Acquired Infections
Sponsored by Schering-Plough
Registration and Dinner: 7:30 - 8:00 PM
Presentations: 8:00 - 10:00 PM
Location: Washington Convention Center, Room 207 Register online at:
www.cerebrio.com/meetings/icaac-idsa
Community-acquired infections that require hospitalization, such as skin and skin structure infections (SSSI), community-acquired pneumonia (CAP), and complicated intra-abdominal infections (cIAI), are associated with high morbidity and mortality. Because the epidemiology and resistance patterns of the causative pathogens vary over time and between regions, physicians need updated information on managing these infections. The proper selection of antimicrobial therapy can improve outcomes and reduce the emergence of resistant bacterial strains. The first presentation in this symposium will describe recent changes in the bacterial etiology of SSSI (including MRSA), the available treatment options, and strategies to reduce antimicrobial resistance. The next lecture will focus on individualizing therapy for hospitalized CAP patients based on various clinical and microbial characteristics, and will outline the most recent treatment guidelines. The last presentation will review the management of cIAI according to current guidelines. It will also include a discussion of newer therapeutic options for cIAI.
Face the Nation: HIV in 2008 - Experts Address the Issues- A National Debate on the Vital Issues Impacting HIV Management
Sponsored by Gilead Sciences Medical Affairs, Bristol-Myers Squibb and Monogram Biosciences
Registration and Dinner: 7:30 - 8:00 PM
Presentations: 8:00 - 10:00 PM
Location: Washington Convention Center, Ballroom A Register online at:
http://www.regonline.com/facethenation
The program will offer an engaging, thought-provoking and informative discussion on new understanding and guiding principles in the optimal treatment of HIV. The format will be that of an interactive Town Hall meeting. The moderator will pose questions, and expert faculty members will have the opportunity to respond with supporting data.
Resistance Wars III: On the Frontlines of Serious Infections - New Strategies to Optimize Outcomes In An Era of Resistance
Sponsored by Ortho-McNeil, Inc.
Registration and Dinner: 7:30 - 8:00 PM
Presentations: 8:00 - 10:30 PM
Location: Washington Convention Center, Room 146 Register online at:
www.synermedregistration.com/RESISTANCEWARS3
Antimicrobial resistance continues to rapidly evolve, presenting increasing challenges to today's clinicians. For the third consecutive year, this satellite symposium will provide a comprehensive update on the latest ways to meet those challenges. The fight against antimicrobial-resistant infections requires a multifaceted approach. Currently, new strategies, federal reforms, and pharmacologic approaches to prevent and treat antibiotic-resistant infections are being explored in many areas. Expert faculty will present current and emerging management strategies on the horizon for pneumonia, skin, and surgical site infections. An interactive question and answer session with the faculty will complete this dynamic, evidence-based program.
Monday, October 27
MRSA: Managing an Elusive Pathogen
Sponsored by National Foundation for Infectious Diseases
Breakfast: 6:30 - 7:00 AM
Symposium: 7:00 - 9:00 AM
Location: Washington Convention Center, Ballroom A
Regsiter online at:
http://www.agcomm.com/NewFiles/MRSA_08.html
Physicians and the public have been increasingly aware of issues related to MRSA infections in both the adult and pediatric populations. Traditionally considered to be a health-care associated pathogen, in the last decade MRSA has been recognized as a common cause of serious and often invasive infections. Now community-associated MRSA strains have come full circle: in several studies, they have been found to cause nearly half of the nosocomial MRSA bacteremias. The rise of MRSA infections outside and inside the hospital has led to emphasis on infection control and public health measures. In particular, questions remain about surveillance, isolation measures and decolonization. The need for a spectrum of treatment options related to the individual patient and severity of illness is clear. Antibiotic selection is complicated by rising rates of resistance to antibiotics traditionally used in this setting. While patients with limited infections may not require antimicrobial treatment, others require many weeks of parenteral therapy, extending beyond the need for hospitalization in an acute care setting. Expertise in the selection, education and management of patients who complete antibiotic therapy for MRSA at home or in other sites outside the hospital is vital to successful outcomes.
Monday, October 27 (cont.)
Location: Washington Convention Center
Changing Paradigms in Treating Complicated Infections/Resistant Bacteria
Sponsored by Forest Laboratories, Inc.
Registration and Dinner: 7:30 - 8:30 PM
Presentations: 8:30 - 10:30 PM
Location: Washington Convention Center, Ballroom C Register online at:
WWW.SCIENTIFIC-FRONTIERS.COM/ICAAC-ID
The management of patients with complicated infections is an evolving process. IDSA guidelines are currently changing to accommodate the changes in epidemiology and incidence of resistant strains of bacteria in cSSSI and CAP, and to foster the concept of antimicrobial stewardship. In addition, new antimicrobial agents with unique pharmacodynamic properties and safety and efficacy profiles against resistant gram-positive and negative bacteria are emerging to challenge the notion that combination antimicrobial therapy is needed in treating these infections. Clinicians who manage patients with complicated infections involving antibiotic-resistant organisms must keep abreast of these changes.
A Global Perspective: Rapid Molecular Diagnostics for the Prevention of Staphylococcus aureus and MRSA Infections
Sponsored by BD
Registration and Dinner: 7:30 - 8:30 PM
Presentations: 8:30 - 10:30 PM
Location: Washington Convention Center, Room 146
The Symposium will focus on the new technologies and clinical applications for the management of Methicillin Resistant Staphylococcus aureus.
Solving the Complexities of Treating Antiretroviral- Experienced Patients
Sponsored by Pfizer
Registration and Dinner: 7:30 - 8:00 PM
Presentations: 8:00 - 10:30 PM
Location: Washington Convention Center, Ballroom A
Register online at:
www.sciuseducation.com
In HIV/AIDS, selection of the appropriate ARV-therapy for ART-experienced individuals is dependent on multiple factors, therefore, no specific guidance is provided by the DHHS Guidelines. This interactive symposium will discuss current and emerging ARV therapies and review the clinical data supporting the advancements in and use of both diagnostic testing and HAART in the treatment antiretroviral-experienced patients. Interactive discussions with expert panel members will facilitate participation by audience members in the utilization of case specific scenarios to improve their ability to design optimal and individualized treatment approaches for their ART-experienced patients. The program will address the difficulties associated with designing optimal treatment regimens for treatment-experienced patients, as well as diagnostic testing options for this HIV/AIDS population.
Tuesday, October 28
Antiviral Therapy for Influenza: A Case-Based Approach for Optimal Management
Sponsored by BioCryst
Breakfast: 6:00 - 6:30 AM
Presentations: 6:30 - 8:30 AM
Location: Renaissance Washington DC, Grand Ballroom
Register online at:
https://secure.intmedpress.com/flu2008
An increase in pediatric deaths, emergence of influenza strains resistant to current antiviral treatments, and ongoing reports of human cases of highly pathogenic avian influenza have heightened awareness that influenza is not always a mild, self-limiting disease. These developments have renewed interest in better diagnostic tests and treatments for influenza infection. Further, there is great interest among CDC and WHO officials in improving clinical outcomes in patients with severe influenza illness.
This symposium will address the multifaceted challenges of influenza management in view of recent guideline updates. The practical clinical management of severe influenza illness will be emphasized and illustrated through case studies from actual patients. Current thinking on the pandemic potential of different viruses and pandemic planning will be reviewed. Finally, new antiviral agents in development will be discussed in view of the alarming increase in viral resistance to existing neuraminidase inhibitors.